Generated by AI
Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, CAR T cell therapies for cancer and autoimmune disease. The company’s current work centers on investigational off-the-shelf cell therapy candidates designed to be manufactured from healthy donor cells and delivered more readily to patients than individualized treatments. Its pipeline includes programs targeting blood cancers, solid tumors, and autoimmune disorders, with emphasis on areas such as large B-cell lymphoma, renal cell carcinoma, and other oncology indications. Allogene Therapeutics also develops supporting technologies and manufacturing capabilities that are intended to improve the consistency, scalability, and accessibility of its cell therapy platform. Headquartered in South San Francisco, California, Allogene Therapeutics plays a specialized role in the immuno-oncology market as a developer of next-generation cell therapies for complex diseases.
Website210 East Grand Avenue
South San Francisco, CA, 94080
United States
The latest articles about ALLO.
Summary of Nov 17's posts. Generated by AI.
Summary of Oct 15's posts. Generated by AI.
Summary of Feb 21's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Investors talking about ALLO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.